trial

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

NCTId NCT00347425
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 286 (actual)
Sponsored by Solvay Pharmaceuticals
Primary completion 2008-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
286 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2006-12
Primary completion
2008-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
AripiprazoleOlanzapineRisperidoneQuetiapineZiprasidone

Sponsors

Solvay PharmaceuticalsLead Sponsor
H. Lundbeck A/SCollaborator
Wyeth is now a wholly owned subsidiary of PfizerCollaborator

Investigators

1
Global Clinical Director SolvayStudy Director

Sites

122 total
Birmingham, United StatesLittle Rock, United StatesAnaheim, United StatesCerritos, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesLa Palma, United StatesLong Beach, United StatesOceanside, United StatesParamount, United StatesPasadena, United States

Linked catalysts

1
Switch Study of Existing Atypical Antipsychotics to Bifeprunox — primary completion2008-02

Facts & assertions

4 sourced
Enrollment
286
Phase
PHASE3
Primary Completion Date
2008-02
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Olanzapine
drug
Risperidone
drug
Quetiapine
drug
Ziprasidone
drug
lead_sponsor
Solvay Pharmaceuticals
company
collaborator
H. Lundbeck A/S
company
Wyeth is now a wholly owned subsidiary of Pfizer
company
indication
Schizophrenia and Schizoaffective Disorder
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Global Clinical Director Solvay
person